Literature DB >> 20596761

A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy.

Stuart Ibsen1, Eran Zahavy, Wolf Wrasdilo, Michael Berns, Michael Chan, Sadik Esener.   

Abstract

PURPOSE: Doxorubicin (DOX) is a very effective anticancer agent. However, in its pure form, its application is limited by significant cardiotoxic side effects. The purpose of this study was to develop a controllably activatable chemotherapy prodrug of DOX created by blocking its free amine group with a biotinylated photocleavable blocking group (PCB).
METHODS: An n-hydroxy succunamide protecting group on the PCB allowed selective binding at the DOX active amine group. The PCB included an ortho-nitrophenyl group for photo cleavability and a water-soluble glycol spacer arm ending in a biotin group for enhanced membrane interaction.
RESULTS: This novel DOX-PCB prodrug had a 200-fold decrease in cytotoxicity compared to free DOX and could release active DOX upon exposure to UV light at 350 nm. Unlike DOX, DOX-PCB stayed in the cell cytoplasm, did not enter the nucleus, and did not stain the exposed DNA during mitosis. Human liver microsome incubation with DOX-PCB indicated stability against liver metabolic breakdown.
CONCLUSIONS: The development of the DOX-PCB prodrug demonstrates the possibility of using light as a method of prodrug activation in deep internal tissues without relying on inherent physical or biochemical differences between the tumor and healthy tissue for use as the trigger.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596761      PMCID: PMC2916115          DOI: 10.1007/s11095-010-0183-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Transdermal photopolymerization for minimally invasive implantation.

Authors:  J Elisseeff; K Anseth; D Sims; W McIntosh; M Randolph; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Photochemical control of the infectivity of adenoviral vectors using a novel photocleavable biotinylation reagent.

Authors:  Mark W Pandori; David A Hobson; Jerzy Olejnik; Edyta Krzymanska-Olejnik; Kenneth J Rothschild; Abraham A Palmer; Tamara J Phillips; Takeshi Sano
Journal:  Chem Biol       Date:  2002-05

3.  Internet-based robotic laser scissors and tweezers microscopy.

Authors:  Elliot L Botvinick; Michael W Berns
Journal:  Microsc Res Tech       Date:  2005-10       Impact factor: 2.769

4.  Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes.

Authors:  A D Lewis; D H Lau; G E Durán; C R Wolf; B I Sikic
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

5.  The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.

Authors:  K Breistøl; H R Hendriks; D P Berger; S P Langdon; H H Fiebig; O Fodstad
Journal:  Eur J Cancer       Date:  1998-09       Impact factor: 9.162

6.  Absorption spectrum of DNA for wavelengths greater than 300 nm.

Authors:  J C Sutherland; K P Griffin
Journal:  Radiat Res       Date:  1981-06       Impact factor: 2.841

7.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 8.  Tumor-activated prodrugs--a new approach to cancer therapy.

Authors:  William A Denny
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

Review 9.  Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Authors:  Risto S Cvetković; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

10.  In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.

Authors:  Yuta Shibamoto; Yukihiro Tachi; Kazuhito Tanabe; Hiroshi Hatta; Sei-Ichi Nishimoto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

View more
  16 in total

1.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

Review 2.  Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Authors:  Danielle Harake; Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Future Cardiol       Date:  2012-07

3.  Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin.

Authors:  Carolyn Schutt; Stuart Ibsen; Eran Zahavy; Santosh Aryal; Stacey Kuo; Selin Esener; Michael Berns; Sadik Esener
Journal:  Pharm Res       Date:  2017-08-08       Impact factor: 4.200

4.  Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.

Authors:  Stuart Ibsen; Eran Zahavy; Wolf Wrasidlo; Tomoko Hayashi; John Norton; Yongxuan Su; Stephen Adams; Sadik Esener
Journal:  Photochem Photobiol       Date:  2013-03-06       Impact factor: 3.421

5.  Development of a tumor-specific photoactivatable doxorubicin prodrug.

Authors:  Albert W Girotti; Giorgio Minotti
Journal:  Photochem Photobiol       Date:  2013-09-03       Impact factor: 3.421

6.  Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.

Authors:  Nirupama Sabnis; Maya Nair; Mervyn Israel; Walter J McConathy; Andras G Lacko
Journal:  Int J Nanomedicine       Date:  2012-02-22

7.  Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles.

Authors:  Yan Chen; Ying Wan; Yi Wang; Haijun Zhang; Zhijun Jiao
Journal:  Int J Nanomedicine       Date:  2011-10-18

8.  Spatiotemporal Control of Doxorubicin Delivery from "Stealth-Like" Prodrug Micelles.

Authors:  Li Kong; Dimitrios Poulcharidis; Gregory F Schneider; Frederick Campbell; Alexander Kros
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

Review 9.  Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment.

Authors:  Stuart Ibsen; Carolyn E Schutt; Sadik Esener
Journal:  Drug Des Devel Ther       Date:  2013-05-03       Impact factor: 4.162

10.  The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics.

Authors:  Yuxia Deng; Haijun Zhang
Journal:  Int J Nanomedicine       Date:  2013-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.